acquired
Stage
1
Investors
About
Immune Design was an immunotherapy company that developed in vivo vaccine and therapeutic platforms to activate antigen-specific cytotoxic immune responses for cancer and infectious diseases. The company advanced clinical-stage immunotherapies and was acquired by Merck in 2019.
Explore Immune Design's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.